Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Abbott
• Treatments: Amprenavir; HIV Protease Inhibitors; Protease Inhibitors; Ritonavir; Saquinavir